PET/CT in therapy evaluation of patients with lung cancer

Tine Nøhr Christensen, Seppo W Langer, Andreas Kjaer, Barbara Malene Fischer, Natasha Hemicke Langer

8 Citations (Scopus)

Abstract

FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

Original languageEnglish
JournalExpert Review of Anticancer Therapy
Volume14
Issue number5
Pages (from-to)595-620
Number of pages26
ISSN1473-7140
DOIs
Publication statusPublished - May 2014

Keywords

  • Humans
  • Lung Neoplasms
  • Multimodal Imaging
  • Positron-Emission Tomography
  • Tomography, X-Ray Computed

Fingerprint

Dive into the research topics of 'PET/CT in therapy evaluation of patients with lung cancer'. Together they form a unique fingerprint.

Cite this